U.S. dependence on China for essential medicines is structural, encompassing generic drugs, biologics manufacturing, and sensitive biotechnology R&D infrastructure. China's state investment has fostered this reliance, creating a significant risk that Beijing will deliberately withhold pharmaceutical inputs as a tool of economic or political coercion, akin to its actions with rare-earth minerals.
This vulnerability manifests in three archetypes: China's control over raw materials for generic drugs like 94 percent of amoxicillin and 74 percent of heparin; the erosion of U.S. biopharmaceutical manufacturing and clinical trial capacity, with Chinese firms holding approximately thirty-two of fifty-five late-stage monoclonal antibody programs globally; and dependence on China for synthetic DNA, critical for future pharmaceutical innovation. Past shortages of amoxicillin, heparin, and norepinephrine have already forced American hospitals to ration care. Mitigating this requires strategic reserves, allied partnerships, incentivizing domestic production of key starting materials, accelerating U.S. clinical trials, and securing DNA supply chains.
No comments:
Post a Comment